IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires 126,260 Shares of Twist Bioscience Corporation $TWST

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 90.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 265,851 shares of the company’s stock after buying an additional 126,260 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.44% of Twist Bioscience worth $7,481,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Envestnet Asset Management Inc. grew its holdings in shares of Twist Bioscience by 19.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 49,840 shares of the company’s stock valued at $1,402,000 after acquiring an additional 8,246 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Twist Bioscience by 14.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after purchasing an additional 184,726 shares during the last quarter. AlphaQuest LLC boosted its position in Twist Bioscience by 202.6% during the third quarter. AlphaQuest LLC now owns 22,555 shares of the company’s stock valued at $635,000 after purchasing an additional 15,101 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in Twist Bioscience by 2.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,122 shares of the company’s stock valued at $651,000 after purchasing an additional 628 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Twist Bioscience by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after purchasing an additional 71,777 shares during the last quarter.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Company guidance was lifted, highlighting stronger demand (the coverage cites AI-related demand drivers and also flags execution risks). This likely drove optimism about near-term revenue trajectory. Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: An analyst increased TWST’s price target by ~20% to $48.35, signaling improved sell-side sentiment and providing a valuation upside reference for investors. Twist Bioscience (TWST) price target increased by 20.00% to 48.35
• Neutral Sentiment: Despite recent sales, executives retain large stakes (CEO Emily Leproust still owns ~869k shares, CAO and other insiders hold sizable positions). That ongoing ownership can temper concerns about single transaction signals.
• Negative Sentiment: Multiple insiders sold shares this week: CEO Emily Leproust sold 5,001 shares at about $46.58, CAO Robert F. Werner sold 7,175 shares across filings (including a 7,000-share block), SVP Paula Green sold 1,194 shares, and another insider sold ~1,099 shares. These disclosures (SEC filings) can be interpreted as near-term selling pressure or diversification and likely weighed on the stock. CEO SEC Filing

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TWST shares. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Evercore ISI increased their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday. Finally, Stephens assumed coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.88.

Insider Activity

In other news, CEO Emily M. Leproust sold 5,001 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $46.58, for a total transaction of $232,946.58. Following the transaction, the chief executive officer owned 869,312 shares in the company, valued at approximately $40,492,552.96. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam Laponis sold 3,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $40.00, for a total value of $120,000.00. Following the sale, the chief financial officer directly owned 137,031 shares of the company’s stock, valued at approximately $5,481,240. The trade was a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 22,409 shares of company stock valued at $960,099. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $47.10 on Friday. The company has a market cap of $2.89 billion, a P/E ratio of -36.80 and a beta of 2.24. The firm’s fifty day moving average price is $36.54 and its two-hundred day moving average price is $31.94. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $54.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.33.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business’s revenue was up 16.9% on a year-over-year basis. Equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.